JP2024105284A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2024105284A5 JP2024105284A5 JP2024065950A JP2024065950A JP2024105284A5 JP 2024105284 A5 JP2024105284 A5 JP 2024105284A5 JP 2024065950 A JP2024065950 A JP 2024065950A JP 2024065950 A JP2024065950 A JP 2024065950A JP 2024105284 A5 JP2024105284 A5 JP 2024105284A5
- Authority
- JP
- Japan
- Prior art keywords
- rnai construct
- seq
- nucleotides
- pnpla3
- duplex
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 108091030071 RNAI Proteins 0.000 claims 40
- 230000009368 gene silencing by RNA Effects 0.000 claims 40
- 125000003729 nucleotide group Chemical group 0.000 claims 26
- 230000000692 anti-sense effect Effects 0.000 claims 16
- 239000002773 nucleotide Substances 0.000 claims 16
- 108091081021 Sense strand Proteins 0.000 claims 11
- 102100031251 1-acylglycerol-3-phosphate O-acyltransferase PNPLA3 Human genes 0.000 claims 10
- 101001129184 Homo sapiens 1-acylglycerol-3-phosphate O-acyltransferase PNPLA3 Proteins 0.000 claims 10
- 108700028369 Alleles Proteins 0.000 claims 6
- 210000004027 cell Anatomy 0.000 claims 6
- RYYWUUFWQRZTIU-UHFFFAOYSA-K thiophosphate Chemical compound [O-]P([O-])([O-])=S RYYWUUFWQRZTIU-UHFFFAOYSA-K 0.000 claims 4
- 210000005229 liver cell Anatomy 0.000 claims 3
- 108091093094 Glycol nucleic acid Proteins 0.000 claims 2
- 230000000295 complement effect Effects 0.000 claims 2
- 238000000338 in vitro Methods 0.000 claims 2
- 230000005764 inhibitory process Effects 0.000 claims 2
- 239000000203 mixture Substances 0.000 claims 2
- KBCBKZHEGSUDBQ-OFBQIVOGSA-N 9-[(2R,3S,4R,5R)-3,4-dihydroxy-5-(hydroxymethyl)-3-methoxyoxolan-2-yl]-1H-purin-6-one Chemical compound CO[C@@]1([C@@H](O[C@@H]([C@H]1O)CO)N1C=NC=2C(O)=NC=NC1=2)O KBCBKZHEGSUDBQ-OFBQIVOGSA-N 0.000 claims 1
- 208000035657 Abasia Diseases 0.000 claims 1
- -1 bicyclic nucleic acid Chemical class 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 238000011534 incubation Methods 0.000 claims 1
- 108020004999 messenger RNA Proteins 0.000 claims 1
- 108020004707 nucleic acids Proteins 0.000 claims 1
- 102000039446 nucleic acids Human genes 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862777714P | 2018-12-10 | 2018-12-10 | |
| US62/777,714 | 2018-12-10 | ||
| PCT/US2019/065481 WO2020123508A2 (en) | 2018-12-10 | 2019-12-10 | Rnai constructs for inhibiting pnpla3 expression and methods of use thereof |
| JP2021532216A JP2022511550A (ja) | 2018-12-10 | 2019-12-10 | ＰＮＰＬＡ３発現を阻害するためのＲＮＡｉコンストラクト |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021532216A Division JP2022511550A (ja) | 2018-12-10 | 2019-12-10 | ＰＮＰＬＡ３発現を阻害するためのＲＮＡｉコンストラクト |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024105284A JP2024105284A (ja) | 2024-08-06 |
| JP2024105284A5 true JP2024105284A5 (https=) | 2025-03-07 |
Family
ID=69024749
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021532216A Pending JP2022511550A (ja) | 2018-12-10 | 2019-12-10 | ＰＮＰＬＡ３発現を阻害するためのＲＮＡｉコンストラクト |
| JP2024065950A Pending JP2024105284A (ja) | 2018-12-10 | 2024-04-16 | ＰＮＰＬＡ３発現を阻害するためのＲＮＡｉコンストラクト及びその使用方法 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021532216A Pending JP2022511550A (ja) | 2018-12-10 | 2019-12-10 | ＰＮＰＬＡ３発現を阻害するためのＲＮＡｉコンストラクト |
Country Status (22)
| Country | Link |
|---|---|
| US (2) | US20220017906A1 (https=) |
| EP (1) | EP3894555A2 (https=) |
| JP (2) | JP2022511550A (https=) |
| KR (1) | KR20210102932A (https=) |
| CN (2) | CN121320339A (https=) |
| AR (1) | AR117297A1 (https=) |
| AU (1) | AU2019396419B2 (https=) |
| BR (1) | BR112021011061A2 (https=) |
| CA (1) | CA3121510A1 (https=) |
| CL (1) | CL2021001489A1 (https=) |
| CO (1) | CO2021008997A2 (https=) |
| CR (1) | CR20210371A (https=) |
| EA (1) | EA202191629A1 (https=) |
| IL (1) | IL283473A (https=) |
| JO (1) | JOP20210142A1 (https=) |
| MX (2) | MX2021006784A (https=) |
| PE (1) | PE20211225A1 (https=) |
| PH (1) | PH12021551326A1 (https=) |
| SG (1) | SG11202105711SA (https=) |
| TW (1) | TW202039843A (https=) |
| UY (1) | UY38503A (https=) |
| WO (1) | WO2020123508A2 (https=) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN115927335A (zh) | 2015-04-13 | 2023-04-07 | 阿尔尼拉姆医药品有限公司 | 类血管生成素3（ANGPTL3）iRNA组合物及其使用方法 |
| UY38003A (es) * | 2017-12-12 | 2019-06-28 | Amgen Inc | Construcciones de arni para inhibir la expresión de pnpla3 y métodos de uso de las mismas |
| WO2021154791A1 (en) | 2020-01-28 | 2021-08-05 | Regeneron Pharmaceuticals, Inc. | Non-human animals comprising a humanized pnpla3 locus and methods of use |
| CA3209418A1 (en) * | 2021-04-14 | 2022-10-20 | Utsav SAXENA | Compositions and methods for modulating pnpla3 expression |
| EP4347823A1 (en) * | 2021-06-02 | 2024-04-10 | Alnylam Pharmaceuticals, Inc. | Patatin-like phospholipase domain containing 3 (pnpla3) irna compositions and methods of use thereof |
| US20250243491A1 (en) * | 2021-09-01 | 2025-07-31 | Aligos Therapeutics, Inc. | Pnpla3-targeting short interfering rna (sirna) molecules and uses thereof |
| AU2023313030A1 (en) * | 2022-07-27 | 2025-01-09 | E-Therapeutics Plc | Nucleic acid compounds |
| WO2024120412A1 (en) * | 2022-12-07 | 2024-06-13 | Shanghai Argo Biopharmaceutical Co., Ltd. | Compositions and methods for inhibiting expression of patatin-like phospholipase domain-containing 3 (pnpla3) |
| AU2023408479A1 (en) * | 2022-12-19 | 2025-05-01 | Arnatar Therapeutics, Inc | Advanced rna targeting (arnatar) |
| EP4665852A1 (en) * | 2023-02-14 | 2025-12-24 | Basecure Therapeutics | Modified double stranded rna agents |
| WO2024182446A2 (en) * | 2023-02-28 | 2024-09-06 | Aligos Therapeutics, Inc. | Pnpla3-targeting short interfering rna (sirna) molecules and uses thereof |
| CN121335980A (zh) * | 2023-05-26 | 2026-01-13 | 阿达尔克斯制药有限公司 | Sod1调节组合物及其使用方法 |
Family Cites Families (40)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4683202A (en) | 1985-03-28 | 1987-07-28 | Cetus Corporation | Process for amplifying nucleic acid sequences |
| US5143854A (en) | 1989-06-07 | 1992-09-01 | Affymax Technologies N.V. | Large scale photolithographic solid phase synthesis of polypeptides and receptor binding screening thereof |
| US5744101A (en) | 1989-06-07 | 1998-04-28 | Affymax Technologies N.V. | Photolabile nucleoside protecting groups |
| US5719262A (en) | 1993-11-22 | 1998-02-17 | Buchardt, Deceased; Ole | Peptide nucleic acids having amino acid side chains |
| US5714331A (en) | 1991-05-24 | 1998-02-03 | Buchardt, Deceased; Ole | Peptide nucleic acids having enhanced binding affinity, sequence specificity and solubility |
| US5539082A (en) | 1993-04-26 | 1996-07-23 | Nielsen; Peter E. | Peptide nucleic acids |
| CA2124087C (en) | 1991-11-22 | 2002-10-01 | James L. Winkler | Combinatorial strategies for polymer synthesis |
| US5981505A (en) | 1993-01-26 | 1999-11-09 | The Trustees Of The University Of Pennsylvania | Compositions and methods for delivery of genetic material |
| US5837533A (en) | 1994-09-28 | 1998-11-17 | American Home Products Corporation | Complexes comprising a nucleic acid bound to a cationic polyamine having an endosome disruption agent |
| US5556752A (en) | 1994-10-24 | 1996-09-17 | Affymetrix, Inc. | Surface-bound, unimolecular, double-stranded DNA |
| US5840710A (en) | 1994-12-09 | 1998-11-24 | Genzyme Corporation | Cationic amphiphiles containing ester or ether-linked lipophilic groups for intracellular delivery of therapeutic molecules |
| US5976567A (en) | 1995-06-07 | 1999-11-02 | Inex Pharmaceuticals Corp. | Lipid-nucleic acid particles prepared via a hydrophobic lipid-nucleic acid complex intermediate and use for gene transfer |
| US7422902B1 (en) | 1995-06-07 | 2008-09-09 | The University Of British Columbia | Lipid-nucleic acid particles prepared via a hydrophobic lipid-nucleic acid complex intermediate and use for gene transfer |
| US5545531A (en) | 1995-06-07 | 1996-08-13 | Affymax Technologies N.V. | Methods for making a device for concurrently processing multiple biological chip assays |
| US5981501A (en) | 1995-06-07 | 1999-11-09 | Inex Pharmaceuticals Corp. | Methods for encapsulating plasmids in lipid bilayers |
| US5854033A (en) | 1995-11-21 | 1998-12-29 | Yale University | Rolling circle replication reporter systems |
| US6217900B1 (en) | 1997-04-30 | 2001-04-17 | American Home Products Corporation | Vesicular complexes and methods of making and using the same |
| CA2294988C (en) | 1997-07-01 | 2015-11-24 | Isis Pharmaceuticals Inc. | Compositions and methods for the delivery of oligonucleotides via the alimentary canal |
| AU747597B2 (en) | 1998-07-20 | 2002-05-16 | Inex Pharmaceuticals Corporation | Liposomal encapsulated nucleic acid-complexes |
| US7833992B2 (en) | 2001-05-18 | 2010-11-16 | Merck Sharpe & Dohme | Conjugates and compositions for cellular delivery |
| US7491805B2 (en) | 2001-05-18 | 2009-02-17 | Sirna Therapeutics, Inc. | Conjugates and compositions for cellular delivery |
| US6693187B1 (en) | 2000-10-17 | 2004-02-17 | Lievre Cornu Llc | Phosphinoamidite carboxlates and analogs thereof in the synthesis of oligonucleotides having reduced internucleotide charge |
| US20030130186A1 (en) | 2001-07-20 | 2003-07-10 | Chandra Vargeese | Conjugates and compositions for cellular delivery |
| US7109165B2 (en) | 2001-05-18 | 2006-09-19 | Sirna Therapeutics, Inc. | Conjugates and compositions for cellular delivery |
| US9181551B2 (en) | 2002-02-20 | 2015-11-10 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA) |
| CA2487274A1 (en) | 2002-05-06 | 2003-11-13 | Nucleonics Inc. | Spermine chemically linked to lipids and cell-specific targeting molecules as a transfection agent |
| US7723509B2 (en) | 2003-04-17 | 2010-05-25 | Alnylam Pharmaceuticals | IRNA agents with biocleavable tethers |
| US7851615B2 (en) | 2003-04-17 | 2010-12-14 | Alnylam Pharmaceuticals, Inc. | Lipophilic conjugated iRNA agents |
| ES2702942T3 (es) | 2003-04-17 | 2019-03-06 | Alnylam Pharmaceuticals Inc | Agentes de ARNi modificados |
| US8017762B2 (en) | 2003-04-17 | 2011-09-13 | Alnylam Pharmaceuticals, Inc. | Modified iRNA agents |
| CA2685127C (en) | 2007-04-23 | 2019-01-08 | Alnylam Pharmaceuticals, Inc. | Glycoconjugates of rna interference agents |
| WO2009073809A2 (en) | 2007-12-04 | 2009-06-11 | Alnylam Pharmaceuticals, Inc. | Carbohydrate conjugates as delivery agents for oligonucleotides |
| AR090905A1 (es) | 2012-05-02 | 2014-12-17 | Merck Sharp & Dohme | Conjugados que contienen tetragalnac y peptidos y procedimientos para la administracion de oligonucleotidos, composicion farmaceutica |
| EP3564374A1 (en) | 2013-06-21 | 2019-11-06 | Ionis Pharmaceuticals, Inc. | Compositions and methods for modulation of target nucleic acids |
| CA2976445A1 (en) * | 2015-02-13 | 2016-08-18 | Alnylam Pharmaceuticals, Inc. | Patatin-like phospholipase domain containing 3 (pnpla3) irna compositions and methods of use thereof |
| WO2017048620A1 (en) * | 2015-09-14 | 2017-03-23 | Alnylam Pharmaceuticals, Inc. | Polynucleotide agents targeting patatin-like phospholipase domain containing 3 (pnpla3) and methods of use thereof |
| US10036024B2 (en) * | 2016-06-03 | 2018-07-31 | Purdue Research Foundation | siRNA compositions that specifically downregulate expression of a variant of the PNPLA3 gene and methods of use thereof for treating a chronic liver disease or alcoholic liver disease (ALD) |
| JP2020522510A (ja) * | 2017-06-02 | 2020-07-30 | ウェイブ ライフ サイエンシズ リミテッドＷａｖｅ Ｌｉｆｅ Ｓｃｉｅｎｃｅｓ Ｌｔｄ． | オリゴヌクレオチド組成物及びその使用方法 |
| CA3065523A1 (en) * | 2017-06-02 | 2018-12-06 | Wave Life Sciences Ltd. | Oligonucleotide compositions and methods of use thereof |
| UY38003A (es) * | 2017-12-12 | 2019-06-28 | Amgen Inc | Construcciones de arni para inhibir la expresión de pnpla3 y métodos de uso de las mismas |
-
2019
- 2019-12-10 CR CR20210371A patent/CR20210371A/es unknown
- 2019-12-10 PE PE2021000850A patent/PE20211225A1/es unknown
- 2019-12-10 EP EP19828524.9A patent/EP3894555A2/en active Pending
- 2019-12-10 UY UY0001038503A patent/UY38503A/es not_active Application Discontinuation
- 2019-12-10 SG SG11202105711SA patent/SG11202105711SA/en unknown
- 2019-12-10 JP JP2021532216A patent/JP2022511550A/ja active Pending
- 2019-12-10 WO PCT/US2019/065481 patent/WO2020123508A2/en not_active Ceased
- 2019-12-10 CN CN202511224281.3A patent/CN121320339A/zh active Pending
- 2019-12-10 BR BR112021011061-5A patent/BR112021011061A2/pt unknown
- 2019-12-10 KR KR1020217021155A patent/KR20210102932A/ko not_active Ceased
- 2019-12-10 AR ARP190103607A patent/AR117297A1/es unknown
- 2019-12-10 EA EA202191629A patent/EA202191629A1/ru unknown
- 2019-12-10 US US17/312,721 patent/US20220017906A1/en active Pending
- 2019-12-10 PH PH1/2021/551326A patent/PH12021551326A1/en unknown
- 2019-12-10 AU AU2019396419A patent/AU2019396419B2/en active Active
- 2019-12-10 TW TW108145175A patent/TW202039843A/zh unknown
- 2019-12-10 CN CN201980081364.8A patent/CN113166761B/zh active Active
- 2019-12-10 CA CA3121510A patent/CA3121510A1/en active Pending
- 2019-12-10 MX MX2021006784A patent/MX2021006784A/es unknown
-
2021
- 2021-05-26 IL IL283473A patent/IL283473A/en unknown
- 2021-06-08 MX MX2026000462A patent/MX2026000462A/es unknown
- 2021-06-08 CL CL2021001489A patent/CL2021001489A1/es unknown
- 2021-06-09 JO JOP/2021/0142A patent/JOP20210142A1/ar unknown
- 2021-07-08 CO CONC2021/0008997A patent/CO2021008997A2/es unknown
-
2024
- 2024-04-16 JP JP2024065950A patent/JP2024105284A/ja active Pending
-
2025
- 2025-01-17 US US19/029,290 patent/US20250320502A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2024105284A5 (https=) | ||
| JP2022078069A (ja) | 二本鎖ＲＮＡによるα－１アンチトリプシンの特異的阻害のための方法及び組成物 | |
| JP2022511550A5 (https=) | ||
| JP2021506238A5 (https=) | ||
| JP2011505833A5 (https=) | ||
| JP2011511636A5 (https=) | ||
| JP2014527401A5 (https=) | ||
| JP2009513144A5 (https=) | ||
| WO2007056153B1 (en) | Peptide-dicer substrate rna conjugates as delivery vehicles for sirna | |
| JP2017528441A5 (https=) | ||
| JP2024512635A5 (https=) | ||
| JP2022534402A5 (https=) | ||
| JP2023503635A (ja) | Ｒｎａ分子を合成する方法 | |
| JP2009531433A5 (https=) | ||
| EP4282966A1 (en) | Oligonucleotides conjugated to oleic acid and uses thereof | |
| JP2014050389A (ja) | マイクロ−ｒｎａおよびその前駆体にハイブリダイズしうる核酸を用いるエリスロポエチンの増加 | |
| US20250376684A1 (en) | Threose nucleic acid antisense oligonucleotides and methods thereof | |
| JP2025512771A5 (https=) | ||
| JP2021513851A5 (https=) | ||
| US20240336920A1 (en) | Threose nucleic acid antisense oligonucleotides and methods thereof | |
| CN102533742B (zh) | 一种双链核苷酸序列、含其的重组质粒及其构建方法 | |
| CA3254112A1 (en) | ARNI CONSTRUCTIONS THAT INHIBIT PNPLA3 EXPRESSION AND THEIR METHODS OF USE | |
| TW202309286A (zh) | 作為新穎基因靜默技術的非對稱短雙股ｄｎａ及其應用 | |
| CN115807048A (zh) | 一种制备双链rna的方法 | |
| JP2024539097A5 (https=) |